Yazar "Aksan, Feyzullah" seçeneğine göre listele
Listeleniyor 1 - 11 / 11
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Continuing or Discontinuing Mesalamine in Crohn's Disease? A Multinational, Propensity-Matched, Retrospective Cohort Study(Lippincott Williams & Wilkins, 2024) Aksan, Feyzullah; Tanriverdi, Lokman Hekim; Barrera, Layla; Ullman, Thomas[No abstract available]Öğe Efficacy and Safety of Adalimumab in Inducing Clinical Remission in Crohn's Disease: A Meta-Analysis With Subgroup Analysis(Lippincott Williams & Wilkins, 2023) Aksan, Feyzullah; Tanriverdi, Lokman Hekim; Monzur, Farah[Abstract Not Available]Öğe Efficacy and Safety of Adalimumab in Inducing Clinical Remission in Crohn's Disease: A Meta-Analysis With Subgroup Analysis(Lippincott Williams & Wilkins, 2023) Aksan, Feyzullah; Tanriverdi, Lokman Hekim; Monzur, Farah[No abstract available]Öğe Ferric Derisomaltose Compared to Iron Sucrose in Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials(Mdpi, 2026) Tanriverdi, Lokman H.; Sarici, Ahmet; Aksan, Feyzullah; Hernandez, Adrian V.Background/Objectives: There are conflicting results on the effects of ferric derisomaltose (FDM) vs. iron sucrose (IS) for treatment of iron deficiency anemia (IDA). We systematically assessed the efficacy and safety of these treatments. Methods: We searched Ovid MEDLINE, Web of Science, Pubmed, and Cochrane Central for randomized controlled trials (RCTs) comparing the efficacy and/or safety of FDM vs. IS in patients with IDA. The primary efficacy outcome was the change in hemoglobin (Hb) levels at week 4, and the safety outcome was serious or severe hypersensitivity reactions, as defined by a standardized set of Medical Dictionary for Regulatory Activities (MedDRA) terms. Inverse-variance random effects models were used for meta-analyses. Results: Five RCTs were included: two in general IDA (n = 1994), two in non-dialysis chronic kidney disease (n = 1542), and one in hemodialysis patients (n = 344). The evidence was very uncertain about the effect of FDM vs. IS for Hb change at week 4 (mean difference [MD] 0.09 g/dL, 95% CI -0.33 to 0.52; I2 = 84%, very low CoE), serious or severe hypersensitivity reactions (MedDRA A + B + C + D, relative risk [RR] 0.83, 95% CI 0.25 to 2.68; I2 = 0%, very low CoE), Hb change at week 8 (MD 0.04 g/dL, 95% CI -0.08 to 0.15; I2 = 0%, very low CoE), Hb increase of >= 2 g/dL at week 4 (RR 1.16, 95% CI 0.97 to 1.38; I2 = 70%, very low CoE), and anaphylactic reactions (MedDRA A, RR 0.38, 95% CI 0.08 to 1.72; I2 = 0%, very low CoE). Conclusions: We found that FDM vs. IS had little to no effect on outcomes for the treatment of IDA.Öğe Glucagon-like peptide-1 receptor agonists associated with improved clinical outcomes in patients with inflammatory bowel disease: a retrospective cohort study(Springer, 2025) Aksan, Feyzullah; Abboud, Alan; Tanriverdi, Lokman H.; Aroniadis, Olga C.; Monzur, FarahGlucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated anti-inflammatory effects in preclinical models of inflammatory bowel disease (IBD), yet clinical data remain limited. This study aimed to assess the association between GLP-1 RAs exposure and disease-related outcomes, treatment patterns, and healthcare utilization in patients with IBD. We conducted a retrospective, propensity score-matched cohort study using data from the TriNetX Analytics Research Network. Adults diagnosed with Crohn's disease or ulcerative colitis between 2006 and 2022 were matched 1:1 based on GLP-1 RAs exposure. Patients with confounding comorbidities were excluded. Key outcomes included 5-year mortality, IBD-related surgeries and complications, medication use, and healthcare utilization. A total of 11,016 matched IBD patients were included (GLP-1 RAs: n = 5508; no GLP-1 RAs: n = 5508). Exposure to GLP-1 RAs was associated with a significantly lower 5-year mortality rate (8.05% vs 10.03%, hazard ratio [HR] 0.65, 95% confidence interval [CI] 0.54-0.78, p < 0.0001). Rates of IBD-related surgeries (HR 0.53, 95% CI 0.39-0.72) and complications (HR 0.81, 95% CI 0.70-0.93) were also reduced. Moreover, patients in the GLP-1 RAs group experienced fewer overall healthcare encounters (chi(2) = 136.52, p < 0.0001). Significant differences were observed in corticosteroid (p < 0.0001) and advanced biologic use (p < 0.0001), although rank biserial correlation was small (0.04 and - 0.11, respectively), and findings on medication use did not persist in subgroup analyses of ulcerative colitis and Crohn's disease patients. Our findings suggest a potential disease-modifying effect of GLP-1 RAs beyond glycemic control, especially in reducing mortality, complications, surgeries, and healthcare use. However, the clinical relevance of reduced medication use warrants further investigation through prospective trials.Öğe The Impact of Smartphone Applications on Bowel Preparation, Compliance With Appointments, Cost-Effectiveness and Patients' Quality of Life for the Colonoscopy Process: A Scoping Review(Lippincott Williams & Wilkins, 2022) Aksan, Feyzullah; Tanriverdi, Lokman; Figueredo, Carlos; Barrera, Layla Cristal; Hasham, Alia; Jariwala, Sunit[Abstract Not Available]Öğe The impact of smartphone applications on bowel preparation, compliance with appointments, cost-effectiveness, and patients' quality of life for the colonoscopy process: A scoping review(Wolters Kluwer Medknow Publications, 2023) Aksan, Feyzullah; Tanriverdi, Lokman H.; Figueredo, Carlos Jose; Barrera, Layla C.; Hasham, Alia; Jariwala, Sunit P.The aim of this scoping review is to evaluate the impact of smartphone application (SPA) technology in patients undergoing elective colonoscopy to measure compliance with appointments, cost-effectiveness, bowel preparation, and quality of life. The scoping review was performed according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews. Ovid Medline, Web of Science, Science Direct, Scopus, Cochrane Library, and PubMed were screened up to Oct 14, 2020, and bibliographies of the retrieved articles were included. Based on pre-specified inclusion and exclusion criteria, 8 primary studies were included in the final analysis from a total of 3,979 non-duplicate articles. Seven out of eight studies measured the bowel preparation quality. In six of these studies, patients in the smartphone group had a successful bowel preparation when compared with the control arm; on the other hand, one study did not find any differences between groups. Adherence to colonoscopy screening was assessed by one study. Patients in the digital intervention arm were significantly more likely to complete a screening test. Patient satisfaction during the periprocedural period of colonoscopy was assessed by five studies which reported significantly higher patient satisfaction in the intervention arm compared to the control arm. None of the studies measured cost-effectiveness. We came to the conclusion that a well-designed, user-friendly SPA can help and guide patients undergoing colonoscopy through the process of following up on their appointments, adhering to bowel preparation, and better understanding their disease condition. Future trials investigating SPAs should include cost-effectiveness and adherence to appointments as an endpoint.Öğe Ozanimod for Induction and Maintenance of Remission in Ulcerative Colitis: A Systematic Review and Meta-analysis of Randomized Controlled Trials(Lippincott Williams & Wilkins, 2023) Aksan, Feyzullah; Tanriverdi, Lokman Hekim; Monzur, Farah[Abstract Not Available]Öğe Ozanimod for Induction and Maintenance of Remission in Ulcerative Colitis: A Systematic Review and Meta-analysis of Randomized Controlled Trials(Lippincott Williams & Wilkins, 2023) Aksan, Feyzullah; Tanriverdi, Lokman Hekim; Monzur, Farah[No abstract available]Öğe S1P Receptor Modulators Improve Clinical Outcomes in Ulcerative Colitis(Lippincott Williams and Wilkins, 2025) Tanriverdi, Lokman H.; Aksan, Feyzullah; Aroniadis, Olga; Monzur, FarahObjectives: – This systematic review and meta-analysis aimed to evaluate the efficacy and safety of sphingosine-1-phosphate (S1P) receptor modulators for achieving clinical remission and key outcomes in inflammatory bowel disease (IBD) patients and to examine the influence of baseline characteristics. Methods: – MEDLINE (Ovid), PubMed, Web of Science, and Cochrane CENTRAL were searched until January 1, 2024. Randomized controlled trials (RCTs) evaluating S1P receptor modulators in adult IBD patients were included. Meta-analyses used inverse variance random-effects models, with stratified analyses by disease type, prior anti-TNF use, corticosteroid use, disease location, and baseline Mayo score. Results: – Six RCTs involving 1744 patients (male: 58.8%; age: 41.1±13.5 y) were analyzed. S1P modulators significantly improved clinical remission versus placebo in induction (RR: 2.22; 95% CI: 1.30-3.80) and maintenance phases (RR: 2.79; 95% CI: 1.72-4.54). For UC patients, induction remission was notably higher with S1P modulators (RR: 2.69; 95% CI: 1.98-3.65). Stratified analyses indicated consistent efficacy across disease location (P=0.15), corticosteroid use (P=0.20), and Mayo scores (P=0.53). Prior anti-TNF-naive patients experienced greater benefits (P=0.04). Maintenance-phase remission rates favored etrasimod (RR: 4.26; 95% CI: 2.36-7.69) over ozanimod (RR: 2.09; 95% CI: 1.54-2.84; P=0.035). Secondary outcomes, including clinical response, endoscopic and histologic remission, mucosal healing, and corticosteroid-free remission, were also significantly improved. Overall, adverse events were more frequent with S1P modulators (RR: 1.18; 95% CI: 1.07-1.30); serious adverse events, infections, mortality, and cardiac events were comparable. Conclusions: – S1P modulators improved remission rates and secondary outcomes in UC with a generally favorable safety profile. More data on CD are needed. © 2025Öğe Sex-specific Response Patterns to Tricyclic Antidepressants in Patients With Diarrhea-Predominant Irritable Bowel Syndrome: A Propensity-Matched, Retrospective Cohort Study(Lippincott Williams & Wilkins, 2024) Aksan, Feyzullah; Tanriverdi, Lokman Hekim; Aroniadis, Olga C.[No abstract available]
